预约演示
Maze and Sanofi sign licence agreement for Pompe disease therapy
2023-05-02
临床1期引进/卖出
Muscle biopsy showing large vacuoles in a case of Pompe disease. Credit: Jensflorian / commons.wikimedia.org.
Maze Therapeutics and Sanofi have signed an exclusPompe disease licence agreement for the former’s glycogen synthase 1 (GYS1) programme and oral substrate reduction therapy, MZE001, to treat Pompe disease.
Maze Therapeuticsing dSanofied for other potential indications.MZE001Pompe disease
MZE001ended Reports
ReportsLOA and PTSR Model - Satralizumab in Demyelinating Diseases GlobalData
ReportsLOA and PTSR Model - (Cilnidipine + Tadalafil) in Raynauds Disease GlobalData
The oral GYS1 inhibitor will mitigate Pompe disease by regulating disease-causing glycogen accumulation.
Maze is set to receive a paymCilnidipinem. Tadalafilent iRaynauds Diseasecash and future equity investment to secure the rights for the continued development and commercialisation of MZE001.
Maze will also receive an exclusive licence for associated GYS1-targeting back-up programmes and intellectual property and a further $600m in developmental, regulatory and sales milestones along with royalties upon the successful commercialisation of MZE001.
Maze has GYS1ressed MZE001 through PhaPompe diseaseent and recently disclosed the findings from a study involving healthy volunteers.
“We believe the applMZE001ity of these insights is broad, and as we look ahead, Maze will focus on more common disorders where ultimately we may best apply our expertise and resources to offer the biggest impact for patients.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。